why choose us

Clinical Trials Search

Showing 15,760 of 132,656 result(s)
International Rare Brain Tumor Registry

Status: Completed

Condition: Astroblastoma

Interventions:

Date: 2023-01-23

Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement

Status: Completed

Condition: Advanced Cholangiocarcinoma

Interventions: TAS-120 is an oral FGFR inhibitor

Date: 2023-01-23

A Study of Mezigdomide in Healthy Participants and Participants With Hepatic Impairment

Status: Completed

Condition: Hepatic Impairment

Interventions: Specified dose on specified days

Date: 2023-01-23

RISC Panel Remnant Sample Collection

Status: Completed

Condition: Arthritis, Inflammatory

Interventions: The Synovasure® RISC™ Panel is a laboratory-developed test (LDT) panel (CD Laboratories, Clinical Laboratory Improvement Amendments [CLIA] Registratio

Date: 2023-01-23

Time-Restricted Eating Versus Nutritional Counseling for the Reduction of Radiation or Chemoradiation Tx Side Effects in Patients With Prostate, Cervical, or Rectal Cancers

Status: Completed

Condition: Localized Prostate Carcinoma

Interventions: Undergo collection of blood

Date: 2023-01-23

Aromatherapy With Lavender as Anxiolysis Prior to Cataracts Surgery

Status: NOT_YET_RECRUITING

Condition: Aromatherapy

Interventions:

Participants will have the Bioesse lavender patch placed on the chest, according to manufacturer recommendations.

After the lavender patch ha

Date: 2023-01-23

Surveillance vs. Endoscopic Therapy for Barrett's Esophagus With Low-grade Dysplasia

Status: Completed

Condition: Barretts Esophagus With Dysplasia

Interventions: Endoscopic eradication therapy is a procedure performed to destroy the precancerous cells at the bottom of your esophagus, so that healthy cells can g

Date: 2023-01-23

Potential Drug Interaction Between ALXN2040 and Rosuvastatin

Status: COMPLETED

Condition: Healthy Participants

Interventions: In Treatment Period 1, participants will receive a single oral tablet of rosuvastatin in the morning of Day 1.
In treatment period 2, on the morn

Date: 2023-01-23

Expanded Access Program for Epcoritamab

Status:

Condition:

Interventions: Biological: Epcoritamab
Eligible patients will receive epcoritamab (28-day cycle) that will be administered as subcutaneous (SC) injections until

Date: 2023-01-23

Psychometric Properties of the SMART Feeding Tool

Status: Completed

Condition: Feeding; Difficult, Newborn
Premature Infant Disease
Dysphagia of Newborn
Nurse's Rol

Interventions: Not Provided

Date: 2023-01-23